Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 796

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 796
---
| Additional paid-in capital                                                                                                                                                                                                 | ​ | ​ | ​                | ​ |  742,085 | ​ | ​ | ​ | ​                | ​ |  726,679 | ​ | ​ |
| Accumulated deficit                                                                                                                                                                                                        | ​ | ​ | ​                | ​ | -684,745 | ​ | ​ | ​ | ​                | ​ | -566,232 | ​ | ​ |
| Accumulated other comprehensive loss                                                                                                                                                                                       | ​ | ​ | ​                | ​ |     -260 | ​ | ​ | ​ | ​                | ​ |   -1,672 | ​ | ​ |
| Total stockholders’ equity                                                                                                                                                                                                 | ​ | ​ | ​                | ​ |   57,085 | ​ | ​ | ​ | ​                | ​ |  158,779 | ​ | ​ |
| Total liabilities and stockholders’ equity                                                                                                                                                                                 | ​ | ​ | ​                | $ |  125,844 | ​ | ​ | ​ | ​                | $ |  182,237 | ​ | ​ |

See Notes to Consolidated Financial Statements. F-37

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(amounts in thousands, except share and per share data)

| ​                                                                                         
 ​                                                                                         | ​ 
 ​ | ​ 
 ​ | Year Ended December 31, 
 2023                    |   |           |   | ​ | ​ | 2022 |   |           |   | ​ | ​ | 2021 |   |           |   | ​ 
 ​ |
|:------------------------------------------------------------------------------------------|:--|:--|:------------------------|:--|----------:|:--|:--|:--|:-----|:--|----------:|:--|:--|:--|:-----|:--|----------:|:--|:--|
| Revenue:                                                                                  | ​ | ​ | ​                       | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ |
| Collaborative revenue                                                                     | ​ | ​ | ​                       | $ |    12,936 | ​ | ​ | ​ | ​    | $ |    16,572 | ​ | ​ | ​ | ​    | $ |       706 | ​ | ​ |
| Commercial supply revenue